Navigation Links
Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
Date:6/16/2011

LAWRENCEVILLE, Ga. and CARDIFF, Wales, June 16, 2011 /PRNewswire/ -- Genesis Biosciences, a global leader in custom fermentation, microbial product formulation and antimicrobial product development, announced today that it received the Pulire Innovation Award in the chemical products category for its e card sanitary bin sanitizer. This prestigious award, which honors creative products, solutions and entrepreneurial ideas in the professional cleaning and environmental hygiene field, was presented to Genesis during the Pulire Exhibition in Verona last month. Genesis' e card is the latest addition to its Biosan series of products for treatment of sanitary waste.

(Logo:  http://photos.prnewswire.com/prnh/20110615/MM20879LOGO)

"As a first-time attendee of Pulire, our team is honored to be recognized by industry experts for our cutting-edge technology and innovative approach to the research and development instrumental in the creation of effective antimicrobial products for professional cleaning," stated Conrad Mielcuszny, president and chief executive officer of Genesis Biosciences. "At Genesis Biosciences, we are committed to constantly evolving and improving our technology to bring value to our customers, and this award represents the first of many accomplishments and achievements that our team expects to make this year."

The Pulire Exhibition, a globally respected industry event, is an international trade exhibition for professional cleaning technologies. The Pulire Innovation Award was open to the nearly 300 exhibitors participating in three categories: chemical products, machines and equipment. Three products for each nomination category were short-listed prior to the start of the trade show. These products, showcased by some of the top industry leaders, were characterized by progressive technologies and advanced know-how, and offered improved performance with regard to competitiveness, profitability, functionality, operator safety, reduced operating costs and times and environmental sustainability.

Genesis Biosciences was formed in 2009 when Biotal Technologies and Lawrenceville, Georgia-based Genesis Technologies were first acquired and then merged by the CKM Group. Genesis Biosciences is a market leader in bacteria fermentation and is the first company to develop, manufacture and offer both microbial and antimicrobial products. Based on the knowledge and experience of the company's scientists and lab technicians, the company utilizes its state-of-the-art in-house fermentation equipment and facilities to grow bacteria to the highest quality known in the marketplace. Additionally, Genesis creates solutions for the safe and natural eradication of bacteria using plant oils, essential oils and green chemistry.

About Genesis Biosciences

Genesis Biosciences is a biotechnology company specializing in bacteria fermentation, microbial, antimicrobial and environmentally preferred products and services. The company focuses its efforts on the development of diverse quality-assured products and solutions for a wide range of markets and applications. Genesis Biosciences emphasizes quality in every aspect of its business to ensure the most efficient, cost-effective solutions to meet customers' needs. Genesis Biosciences' U.S. facility is located in Lawrenceville, Georgia, and its European facility is in Cardiff, Wales. For more information, please visit www.genesisbiosciences.com.


'/>"/>
SOURCE Genesis Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
2. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
3. ThermoGenesis Announces China Customer Implements Cord Blood Products
4. Tissue Genesis Begins FDA-Approved Clinical Trial
5. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
6. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
7. Announcing ValGenesis On-Demand SaaS Solution
8. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
9. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
10. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform
11. Genesis Biopharma Appoints L. Stephen Coles M.D., Ph.D. to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):